Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

High hs-CRP weakens tadalafil efficacy against erectile dysfunction

08 Dec 2019

Elevated levels of serum high-sensitivity C-reactive protein (hs-CRP) appear to attenuate the response to tadalafil in patients with erectile dysfunction (ED), a recent study has shown.

The study included 282 men (mean age, 36.6±12.0 years) with ED who underwent 6 weeks of tadalafil therapy. Participants were evaluated using the 6-item version of the International Index of Erectile Function (IIEF-6), penile Doppler studies and hs-CRP measurements both before and after the treatment period. The therapeutic response to tadalafil was the primary outcome.

Almost a quarter of the men (23.8 percent; n=67) had vasculogenic ED, as determined by penile Doppler; the remaining had nonvasculogenic condition. The former group had more severe ED (mean IIEF-6 score, 9.2±4.6 vs 14.8±4.7; p<0.001).

Majority (60.9 percent; n=134) showed positive responses to tadalafil therapy, a further 97.0 percent of whom reported symptomatic improvement. Compliance to the intervention was likewise high at 92.3 percent. Headaches (n=3) and backaches (n=11) were the most common reasons for poor compliance.

Responders had significantly lower median baseline concentrations of hs-CRP (1.5 vs 2.0 mg/L; p=0.034), as well as a greater corresponding decline over time (median change, –18.2 percent vs –8.3 percent; p=0.002).

Other variables that may explain response were nonvasculogenic ED, which was significantly more common among responders (96.3 percent vs 50.0 percent; p<0.001), and ED severity (mean IIEF-6: 15.6±4.5 vs 10.7±4.7; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.